-
CRH plc (the "Company") Form 10-Q for the quarterly period ended September 30, 2024
CRH plc (the "Company") Form 10-Q for the quarterly period ended September 30, 2024
Share
DUBLIN--(BUSINESS WIRE)--
A Form 10-Q for the quarterly period ended September 30, 2024 (the “Form 10-Q”) has been filed with the U.S. Securities and Exchange Commission (the "SEC") today. The Form 10-Q is available to view on the SEC’s website at: https://www.sec.gov. and the Company's website at: https://www.crh.com.
Enquiries
Contact
Neil Colgan
Company Secretary
Tel: 00 3531 6344340
Contacts
CRH plc
More News From CRH plc
CRH announces Early Results of Tender Offers, Exchange Offers and Consent Solicitations for Arcosa, Inc. Notes
NEW YORK--(BUSINESS WIRE)--CRH plc (NYSE: CRH) announced today the early results of the previously announced (i) cash tender offers (the “Tender Offers” and each a “Tender Offer”) by CRH America Finance, Inc. (“CRH AF”), to purchase any and all of the outstanding 4.375% Senior Notes due 2029 (the “2029 Arcosa Notes”) and 6.875% Senior Notes due 2032 (the “2032 Arcosa Notes” and, together with the 2029 Arcosa Notes, the “Arcosa Notes”), issued by Arcosa, Inc. (“Arcosa”), an indirect wholly owned...
CRH announces Cash Tender Offers, Exchange Offers and Consent Solicitations for Arcosa, Inc. Notes
NEW YORK--(BUSINESS WIRE)--In connection with the recent completion of the acquisition of Arcosa, Inc. (“Arcosa”) on October 23, 2026 (the “Arcosa Acquisition”), CRH plc (NYSE: CRH) announced today that CRH America Finance, Inc. (“CRH AF”), an indirect wholly owned subsidiary of CRH plc, has commenced (i) cash tender offers (the “Tender Offers” and each a “Tender Offer”) to purchase any and all of the outstanding 4.375% Senior Notes due 2029 (the “2029 Arcosa Notes”) and 6.875% Senior Notes due...
CRH Reports Third Quarter 2026 Results
NEW YORK--(BUSINESS WIRE)--CRH (NYSE: CRH), the leading provider of building materials, today reported third quarter 2026 financial results. Total revenues of $11.4 billion (Q3 2025: $11.1 billion) were 3% ahead of the prior year driven by positive pricing momentum, resilient underlying demand, and contributions from acquisitions. Net income of $1.2 billion (Q3 2025: $1.5 billion) was lower than the prior year, primarily impacted by Loss on impairments. Adjusted EBITDA* of $2.7 billion was in l...